Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Published:2013-04 Issue:4 Volume:24 Page:916-924
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Rodrigues M.J.,Peron J.,Frénel J.-S.,Vano Y.-A.,Wassermann J.,Debled M.,Picaud F.,Albiges L.,Vincent-Salomon A.,Cottu P.H.

Funder

French National Association of Residents in Oncology

AERIO; Association d'Enseignement et de Recherche des Internes en Oncologie

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/4/916/717584/mds536.pdf

Reference36 articles.

1. Trastuzumab—mechanism of action and use in clinical practice;Hudis;N Engl J Med,2007

2. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial;Gianni;Lancet Oncol,2011

3. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial;Joensuu;J Clin Oncol,2009

4. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31;Perez;J Clin Oncol,2011

5. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery;Cancers;2023-09-14

2. Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2023-04

3. Borderline indications for ovarian suppression: addressing uncertainties with patients;Future Oncology;2022-12

4. Characterization of 940 Chinese patients with triple-positive breast cancer by clinicopathological and treatment outcomes;2022-10-11

5. Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study;Breast Cancer Research and Treatment;2022-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3